News
Fresenius Kabi Recalls Tyenne Injection in US Due to Glass Particle Contamination
Fresenius Kabi is notifying distributors and customers directly about the recall and is arranging for the return of affected products.
E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
Fresenius Kabi is notifying distributors and customers directly about the recall and is arranging for the return of affected products.
Fresenius Kabi holds the exclusive rights to commercialize Dr. Reddy’s Rituximab Biosimilar in the United States.
HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.

